|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.660 EUR | -0.60% |
|
+0.61% | +22.06% |
| 05-12 | TherapeuticsMD announces first quarter 2026 financial results | RE |
| 05-12 | TherapeuticsMD, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
| Market Cap | 22.8M 19.96M 18.45M 17.02M 32.05M 2.19B 32.69M 220M 86.28M 1.07B 85.64M 83.74M 3.7B | P/E 2024 |
-4.55x | P/E 2025 | -30.9x |
|---|---|---|---|---|---|
| Enterprise Value | 21.42M 18.75M 17.33M 15.99M 30.1M 2.06B 30.7M 207M 81.04M 1.01B 80.43M 78.65M 3.47B | EV / Sales 2024 |
6.83x | EV / Sales 2025 | 5.78x |
| Free-Float |
92.55% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | -0.60% | ||
| 1 week | +0.61% | ||
| Current month | -13.99% | ||
| 1 month | +10.67% | ||
| 3 months | -4.60% | ||
| 6 months | -5.14% | ||
| Current year | +22.06% |
| 1 week | 1.65 | 1.69 | |
| 1 month | 1.51 | 1.93 | |
| Current year | 1.31 | 2.3 | |
| 1 year | 1.31 | 2.3 | |
| 3 years | 1.31 | 2.3 | |
| 5 years | 0.11 | 45 | |
| 10 years | 0.11 | 383.75 |
| Manager | Title | Age | Since |
|---|---|---|---|
Marlan Walker
CEO | Chief Executive Officer | 51 | 2022-12-29 |
Joseph Ziegler
DFI | Director of Finance/CFO | 52 | 2023-08-16 |
| Director | Title | Age | Since |
|---|---|---|---|
Cooper Collins
BRD | Director/Board Member | 46 | 2012-02-28 |
Tommy Thompson
CHM | Chairman | 83 | 2012-04-15 |
Gail Naughton
BRD | Director/Board Member | 69 | 2020-03-19 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.60% | +0.61% | - | - | 22.8M | ||
| -2.62% | -6.27% | +44.35% | +12.52% | 306B | ||
| -0.25% | -1.59% | +26.99% | -6.69% | 69.32B | ||
| -1.39% | -7.99% | +30.18% | +96.36% | 9.03B | ||
| +1.16% | -1.99% | +7.49% | +0.32% | 8.48B | ||
| -5.93% | -12.13% | -21.97% | -2.48% | 4.16B | ||
| +8.22% | +7.72% | +20.08% | +37.40% | 4B | ||
| -2.06% | -5.12% | -40.13% | +17.71% | 3.4B | ||
| -1.46% | -2.67% | +37.40% | +55.38% | 2.75B | ||
| +1.57% | +1.00% | +10.61% | -18.97% | 2.15B | ||
| Average | -0.05% | -1.09% | +12.78% | +21.28% | 45.51B | |
| Weighted average by Cap. | +0.13% | -3.97% | +38.50% | +11.12% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 1.76M 1.54M 1.43M 1.31M 2.48M 169M 2.52M 17.01M 6.66M 82.78M 6.61M 6.47M 286M | 3.02M 2.65M 2.45M 2.26M 4.25M 291M 4.33M 29.19M 11.44M 142M 11.35M 11.1M 490M |
| Net income | -2.18M -1.91M -1.76M -1.63M -3.07M -210M -3.13M -21.07M -8.25M -103M -8.19M -8.01M -354M | -569K -498K -460K -425K -800K -54.73M -816K -5.5M -2.15M -26.75M -2.14M -2.09M -92.29M |
| Net Debt | 2.12M 1.85M 1.71M 1.58M 2.97M 204M 3.03M 20.44M 8.01M 99.46M 7.95M 7.77M 343M | -1.39M -1.21M -1.12M -1.03M -1.95M -133M -1.99M -13.39M -5.24M -65.15M -5.21M -5.09M -225M |
Employees
1
Sector
Pharmaceuticals
| Date | Price | Change |
|---|---|---|
| 26-07-14 | €1.660 | -0.60% |
| 26-07-13 | €1.670 | +1.21% |
| 26-07-10 | €1.650 | 0.00% |
| 26-07-09 | €1.650 | -1.79% |
| 26-07-08 | €1.680 | +1.82% |
- Stock Market
- Stocks
- TXMD Stock
- 29TA Stock
Select your edition
All financial news and data tailored to specific country editions
















